<DOC>
	<DOCNO>NCT02917005</DOCNO>
	<brief_summary>This open label , randomize , multicenter , international phase II study premenopausal patient hormone receptor positive , HER2 negative metastatic locally advanced breast cancer . Patients randomize receive either palbociclib + exemestane + OFS ( Arm 1 ) exemestane +OFS ( Arm 2 ) . Treatment continue disease progression , unacceptable toxicity , withdrawal consent .</brief_summary>
	<brief_title>PalbocIclib PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer</brief_title>
	<detailed_description>There strong in-vitro clinical evidence suggest dual inhibition CDK 4/6 ER signal highly effective therapeutic strategy HR+ MBC . With unprecedented success palbociclib PALOMA-1 trial , several phase 2 3 trial underway evaluate agent ( CDK4/6 inhibitor well ) different clinical scenario HR+ breast cancer [ 28 ] .The vast majority trial -if all- test novel agent postmenopausal patient , would render clinical experience agent restrict postmenopausal woman ( median age 62 year PALOMA-1 trial ) The scarcity clinical trial address endocrinal therapy premenopausal woman MBC , least part , relate fact majority woman western country diagnose breast cancer postmenopausal life . However situation rather different many country , include Middle East region , median age woman diagnose breast cancer 50 year , approximately 50 % patient still menstruate . This study first explore therapeutic effect palbociclib combine exemestane ovarian function suppression ( OFS ) premenopausal hormone receptor positive HER2 negative MBC , compare classic approach use OFS plus aromatase inhibitor .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Adult woman ( ≥ 18 year age ) metastatic locally advanced breast cancer ( histologically cytologically proven diagnosis adenocarcinoma breast ) amenable curative treatment surgery radiotherapy . 2 . ER positive tumour : Histological cytological confirmation estrogen and/or progesteronereceptor positive , determined routine IHC . Positivity define ≥1 % positive stained cell . The receptor status determine utilizing assay consistent local laboratory standard . 3 . HER2 negative breast cancer confirm IHC , SISH FISH . 4 . Premenopausal woman : ( definition real menopause simple task relatively young woman , owe potential effect prior chemotherapy /or endocrinal therapy particularly OFS ) define either : . Any age 40 year , irrespective E2 level menstrual history ii . If woman menstrual period time within last 12 month iii . If woman amenorrhea 12 month ( absence chemotherapy ovarian function suppression ) associate serum hormone level NOT postmenopausal range ( either estradiol ( E2 ) &lt; 30 pg/mL folliclestimulating hormone ( FSH ) &lt; 20 mU/mL OR E2 ≥ 30 pg/mL FSH ≥ 20 mU/mL ) [ 30 ] . 5 . Secondary hormonal resistance tamoxifen endocrinal sensitive metastatic disease . Secondary hormonal resistance define recurrence 24 month start adjuvant tamoxifen treatment within 12 month end 5 year adjuvant Tamoxifen ii . Endocrinal sensitive disease define recurrence 12 month end adjuvant tamoxifen treatment de novo metastatic disease 6 . Measurable disease accord RECIST boneonly metastasis . Previously irradiated lesion deem measurable progression document site completion radiation . . Patients must either least one lesion accurately measure ; OR ii . Patients bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease define . 7 . ECOG Performance Status 0 , 1 , &amp; 2 . 8 . Resolution acute toxic effect prior therapy surgical procedure National Cancer Institute ( NCI ) CTCAE Grade 1 ( except alopecia toxicity consider safety risk patient ) . 9 . Adequate organ function define follow criterion : . Absolute neutrophil count ( ANC ) ≥ 1.5 10˄9/L ii . Platelets &gt; 100 x10˄9/L iii . Hemoglobin ( Hgb ) &gt; 9.0g/dL iv . INR &lt; 2 v. Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5x ULN ( &lt; 5 hepatic metastasis present ) vi . Total serum bilirubin &lt; 1.5 x ULN ( &lt; 3 x ULN patient know Gilberts Syndrome ) vii . Serum creatinine &lt; 1.5 x ULN viii . QTc &lt; 470 msec ( base mean value triplicate ECGs ) . 10 . Written inform consent obtain trial related activity accord local guideline . 1 . Postmenopausal woman . Postmenopausal status define age &gt; 40years amenorrhea 12 month , associate serum hormonal level postmenopausal range ( either estradiol ( E2 ) &lt; 30 pg/mL folliclestimulating hormone ( FSH ) &lt; 20 mU/mL E2 ≥ 30 pg/mL FSH ≥ 20 mU/mL ) [ 30 ] , absence chemotherapy , tamoxifen , OFS . 2 . Patients primary endocrinal resistance , define recurrence within 24 month start adjuvant tamoxifen treatment . 3 . Symptomatic and/or life threaten visceral metastasis i. Diffuse lymphangitic carcinomatosis . ii . Bulky liver pulmonary metastasis 4 . Patients nonmeasurable lesion bone metastasis define ( e.g. , pleural effusion , ascites , etc. ) . 5 . Patients receive hormonal treatment neo/adjuvant tamoxifen ± LHRH agonist early breast cancer . 6 . Patients receive prior chemotherapy metastatic recurrent breast cancer . 7 . Another malignancy within 5 year prior enrolment exception adequately treat insitu carcinoma cervix , uterus , basal squamous cell carcinoma nonmelanomatous skin cancer . 8 . Uncontrolled ( clinically radiologically progressive ) CNS metastasis , carcinomatous meningitis , leptomeningeal disease . 9 . Major surgery within 3 week first study treatment . 10 . Chemotherapy , radiotherapy , anticancer therapy within 2 week randomization . Patients previously receive radiotherapy 25 % bone marrow eligible independent receive . 11 . Current treatment anticancer therapy advance disease ; experimental treatment another clinical trial ; therapeutic dos anticoagulant . N.B . Low dose anticoagulant deep vein thrombosis prophylaxis allow . Low molecular weight heparin allow . Aspirin permit . 12 . Active bleeding diathesis . 13 . History noncompliance medical regimen . Patients unwilling unable comply protocol . 14 . Pregnant breast feed woman use effective birth control method . Adequate contraceptive must use throughout trial 8 week last study drug administration . Patients must negative serum pregnancy test within 7 day prior first administration study drug . 15 . Prior hematopoietic stem cell bone marrow transplantation . 16 . Current use food drug know potent CYP3A4 inhibitor , drug know potent CYP3A4 inducer , drug know prolong QT interval . 17 . Known possible hypersensitivity goserelin adjuvant setting . 18 . Any severe and/or uncontrolled medical condition : i. Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction &lt; 6months prior enrollment , serious uncontrolled cardiac arrhythmia ii . Uncontrolled diabetes define fast serum glucose &gt; 3 x ULN iii . Acute chronic active infectious disorder ( except Hepatitis B Hepatitis C positive patient ) nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy iv . Known human immunodeficiency virus infection v. Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>hormone receptor positive , HER2 negative</keyword>
	<keyword>palbociclib</keyword>
	<keyword>premenopausal</keyword>
</DOC>